STOCK TITAN
  1. Home
  2. Sec-filings
  3. SABS
  4. [EFFECT] SAB Biotherapeutics, Inc. SEC Filing

[EFFECT] SAB Biotherapeutics, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 7, 2026 5:00 P.M.
Form: S-3
CIK: 0001833214
Company Name: SAB Biotherapeutics, Inc.
File Number: 333-292482

Source: View Original Filing on SEC EDGAR

Stock SABS logo
SAB BIOTHERAPEUTICS INC

NASDAQ:SABS

SABS Rankings

#4510 Ranked by Market Cap
N/A Ranked by Dividends

SABS Latest News

Jan 7, 2026
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
Jan 6, 2026
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
Dec 18, 2025
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
Dec 17, 2025
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
Dec 8, 2025
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

SABS Latest SEC Filings

Dec 18, 2025
[Form 4] SAB Biotherapeutics, Inc. Insider Trading Activity
Dec 18, 2025
[Form 4] SAB Biotherapeutics, Inc. Insider Trading Activity
Dec 18, 2025
[Form 4] SAB Biotherapeutics, Inc. Insider Trading Activity
Dec 18, 2025
[Form 4] SAB Biotherapeutics, Inc. Insider Trading Activity
Dec 18, 2025
[Form 4] SAB Biotherapeutics, Inc. Insider Trading Activity

SABS Stock Data

187.57M
41.72M
14.29%
18.66%
4.23%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
MIAMI BEACH